Lexeo Therapeutics, Inc.(LXEO)
$2.95+0.10 (+3.33%)
LXEO
Lexeo Therapeutics, Inc. financials statements
$2.95
At close:+0.10 (+3.33%)
Want to see LXEO full AI Analyst Report?
Lexeo Therapeutics, Inc. (LXEO) Ratios
311 Followers
Lexeo Therapeutics, Inc. Ratios
LXEO's free cash flow for Q3 2026 was $-28.86M. For the 2026 fiscal year, LXEO's free cash flow was decreased by $-298.00K and operating cash flow was $-28.56M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.21 | 5.52 | 7.21 | 5.58 | 18.35 |
| Quick Ratio | 11.21 | 5.52 | 7.21 | 5.58 | 18.35 |
| Cash Ratio | 3.75 | 1.53 | 7.05 | 5.39 | 18.24 |
| Solvency Ratio | -4.45 | -3.20 | -2.46 | -0.28 | -0.26 |
| Operating Cash Flow Ratio | -5.86 | -3.55 | -3.45 | -3.80 | -5.93 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -30.39 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 166.37M | $ 96.02M | $ 98.02M | $ -129.98M | $ -55.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.07 | 0.08 | 0.14 | 0.00 |
| Debt-to-Equity Ratio | 0.03 | 0.08 | 0.10 | -0.12 | 0.00 |
| Debt-to-Capital Ratio | 0.03 | 0.08 | 0.09 | -0.14 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.26 | 1.23 | -0.86 | -2.46 |
| Debt Service Coverage Ratio | -474.16 | -34.55 | -313.88 | -637.81 | 0.00 |
| Interest Coverage Ratio | -530.37 | -927.77 | -334.21 | -664.93 | 0.00 |
| Debt to Market Cap | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.15 | 0.32 | 0.44 | 0.54 | 0.00 |
| Net Debt to EBITDA | 0.56 | 0.26 | 1.71 | 1.10 | 2.68 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -9049.85% | -3055.04% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -8874.77% | -3054.25% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -9252.14% | -3055.94% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -9063.76% | -3055.04% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -9063.76% | -3055.04% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -9063.76% | -3055.04% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.49% | 92.97% | 96.91% | 97.96% | 99.97% |
| Return on Assets (ROA) | -37.20% | -66.92% | -47.49% | -61.06% | -36.99% |
| Return on Equity (ROE) | -40.52% | -84.16% | -58.48% | 52.48% | 91.04% |
| Return on Capital Employed (ROCE) | -43.38% | -85.23% | -55.90% | -73.14% | -39.13% |
| Return on Invested Capital (ROIC) | -42.92% | -83.43% | -54.73% | -67.39% | -39.13% |
| Return on Tangible Assets | -37.20% | -66.92% | -47.49% | -61.06% | -36.99% |
| Earnings Yield | -18.77% | -47.01% | -18.57% | -23.43% | -20.01% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.05 | 9.52 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.84 | -2.55 | -2.23 | -2.17 | -1.76 |
| Free Cash Flow Per Share | -1.84 | -2.57 | -2.24 | -2.20 | -1.76 |
| Dividend Paid and CapEx Coverage Ratio | -248.26 | -168.71 | -360.58 | -60.55 | -235.01 |
| Capital Expenditure Coverage Ratio | -248.26 | -168.71 | -360.58 | -60.55 | -235.01 |
| Operating Cash Flow Coverage Ratio | -12.50 | -8.18 | -5.11 | -4.05 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -83.43 | -26.66 |
| Free Cash Flow Yield | -18.58% | -39.03% | -16.68% | -21.93% | -17.54% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.34 | -2.13 | -5.39 | -4.27 | -5.00 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 386.78 | 152.66 |
| Price-to-Book (P/B) Ratio | 2.16 | 1.79 | 3.15 | -2.24 | -4.55 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.38 | -2.56 | -5.99 | -4.56 | -5.70 |
| Price-to-Operating Cash Flow Ratio | -5.40 | -2.58 | -6.01 | -4.64 | -5.73 |
| Price-to-Earnings Growth (PEG) Ratio | 0.13 | -0.09 | -0.98 | -0.25 | -0.01 |
| Enterprise Value Multiple | -4.89 | -1.91 | -3.85 | -3.26 | -2.31 |
| Enterprise Value | 477.58M | 184.07M | 247.77M | 189.10M | 117.09M |
| EV to EBITDA | -4.89 | -1.91 | -3.85 | -3.26 | -2.31 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 289.14 | 70.66 |
| EV to Free Cash Flow | -4.83 | -2.25 | -4.15 | -3.41 | -2.64 |
| EV to Operating Cash Flow | -4.85 | -2.27 | -4.16 | -3.47 | -2.65 |
| Tangible Book Value Per Share | 4.60 | 3.68 | 4.26 | -4.49 | -2.21 |
| Shareholders’ Equity Per Share | 4.60 | 3.68 | 4.26 | -4.49 | -2.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 |
| Net Income Per Share | -1.86 | -3.09 | -2.49 | -2.36 | -2.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 75.17 | 27.23 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 18.35 | 4.33 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 2.72 | 0.23 |
| Income Quality | 0.99 | 0.83 | 0.90 | 0.92 | 0.87 |
Currency in USD

